ASBMR Three Year Pre-Meeting Symposia

美国骨与矿物研究学会(ASBMR)，最大的专业、科学和医学 为汇聚临床和实验室科学家而成立的学会，这些科学家参与了对癌症的研究 骨、矿物和肌肉骨骼科学，有举办年度专题会议的成功历史。 自2002年以来，由美国国立卫生研究院R13年度拨款资助。最近，ASBMR获得了两笔为期三年的R13赠款 涵盖2016-2018年和2019-2021年的会前座谈会计划。目前的申请正在寻求资金 提供为期三年的R13赠款，通过重点关注三个具体领域来促进肌肉骨骼疾病领域的发展 2022年、2023年和2024年科学研究奖：1)《罕见病：从分子和机制到 治疗学“；2)”骨健康和疾病中的骨细胞及其作为治疗靶细胞“；3)”能量“ 骨骼发育和疾病中的代谢“。这三个研讨会涵盖了以下高度相关的领域 最近在科学知识和集体方面经历了快速演变的肌肉骨骼研究 导致严重的临床发病率、残疾和死亡率。此R13的总体目标是刺激 进一步的进展将导致改善肌肉骨骼疾病的患者护理 三次研讨会中每一次都是最佳研究人员。座谈会将回顾每个主题领域的最新进展， 与与会者交流思想，促进年轻研究人员和知名研究人员之间的互动。 研讨会与会者将被鼓励参加随后的ASBMR年会，以获得更多 与肌肉骨骼研究人员互动的机会。所有三个研讨会的节目都是由 组委会和前两次研讨会的所有发言者都已确认参加。 演讲者包括成熟的和年轻的调查人员，女性和男性，由于ASBMR约有一半 成员来自美国以外的国家，一些重要的国际演讲者也被邀请。海报 会议、青年调查员颁奖典礼，以及在每次会议结束时的“共进晚餐”之夜是 计划促进青年调查人员与更资深的发言者之间的直接互动。2022年， 研讨会将汇集国际罕见骨病专家，讨论有关骨科疾病的最新进展。 机制和疗法，为临床医生提供如何识别它们的指导，以及从中吸取的教训 直接应用于骨质疏松症等更常见的骨骼疾病的罕见疾病。2023年， 研讨会将综述骨细胞在骨移植中的作用的基础、翻译和临床研究的进展。 骨的生物学和病理生理学，以及如何以骨细胞为治疗目标。骨细胞在成骨细胞中的作用 将讨论机制生物学、激素作用、骨癌和骨细胞内分泌作用。2024年 研讨会将讨论能量代谢在骨骼发育中的作用和最新进展 疾病，包括缺氧的作用和线粒体介导的机制，以及它在 骨骼对合成代谢疗法和代谢性疾病如糖尿病的反应。

The American Society for Bone and Mineral Research (ASBMR), the largest professional, scientific and medical society established to bring together clinical and laboratory-based scientists who are involved in the study of bone, mineral and musculoskeletal science, has had a successful history of conducting annual topical meetings funded by single year NIH R13 grants since 2002. More recently, ASBMR received two, three-year R13 grants to cover pre-meeting symposia programs for 2016-2018 and 2019-2021. The current application seeks funding for a three-year R13 grant to advance the field of musculoskeletal diseases by focusing on three specific areas of scientific research in 2022, 2023 and 2024: 1) “Rare Diseases: From Molecules and Mechanisms to Therapeutics”; 2) “Osteocytes in Bone Health and Disease and as Therapeutic Target Cells”; 3) “Energy Metabolism in Skeletal Development and Disease”. These three symposia cover highly relevant areas of musculoskeletal research that has recently undergone rapid evolution in scientific knowledge and collectively contribute to major clinical morbidity disability and mortality. The overall objective of this R13 is to stimulate further advances that will result in improved patient care for musculoskeletal diseases by bringing together the best researchers for each of the three symposia. The symposia will review the state of the art in each topic area, exchanging ideas with attendees, and stimulating the interaction between young and established researchers. Symposia attendees will be encouraged to attend the subsequent ASBMR Annual Meetings for additional opportunities to interact with musculoskeletal researchers. Programs for all three symposia were developed by an organizing committee, and all speakers for the first two symposia have confirmed their participation. Presenters include established and young investigators, women and men, and, since about half of ASBMR membership is from outside the US, a number of key international speakers have also been invited. Poster sessions, young investigator award presentations, and at the end of each meeting a “dine-around” evening are planned to promote direct interaction between young investigators and more senior speakers. In 2022, the symposium will gather international experts in rare bone diseases to discuss the latest advances on underlying mechanisms and therapies, provide guidance to clinicians on how to recognize them, and lessons learnt from rare diseases that have direct application to more common bone diseases such as osteoporosis. In 2023, the symposium will review the advances in basic, translational and clinical research on the role of osteocytes in the biology and pathophysiology of bone, and how to target osteocytes with therapeutic goals. The osteocyte role in mechanobiology, hormone actions, cancer in bone and osteocyte endocrine actions will be discussed. The 2024 symposium will discuss the recent advances on the role of energy metabolism in skeletal development and disease; including the role of hypoxia and mitochondria-mediated mechanisms, and its involvement in the response of bone to anabolic therapies and metabolic diseases such as diabetes.